Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 8/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357371 | 0.85 | KDM4E (0.40) | KDM4EHSD17B10GAATSHRSMN1; SMN2 | |
| SCHEMBL23728467 | 0.82 | ALDH1A1 (0.53) | KDM4EHSD17B10SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL22834641 | 0.79 | IRAK4 (0.34) | KDM4EALDH1A1PDE2AIRAK4 | |
| SCHEMBL12505413 | 0.76 | IRAK4 (0.43) | KDM4ESMN1; SMN2ALDH1A1TDP1PDE2A | |
| SCHEMBL12505460 | 0.75 | IRAK4 (0.43) | KDM4EALDH1A1TDP1PDE2AIRAK4 | |
| SCHEMBL309283 | 0.75 | KDM4E (0.43) | KDM4EALDH1A1TDP1PDE2AIRAK4 | |
| SCHEMBL310126 | 0.75 | PDE2A (0.59) | KDM4EALDH1A1TDP1PDE2A | |
| SCHEMBL310362 | 0.75 | HSD11B1 (0.49) | KDM4EHSD17B10SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL310187 | 0.75 | KDM4E (0.43) | KDM4EGAATSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL28667748 | 0.75 | KDM4E (0.41) | KDM4EALDH1A1TDP1PDE2AIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-20 | — | — | US | disclosed |
| EP-4100004-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158634-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230122219-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885HSD17B10 2107/4885GAA 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.